Pharmaceutical Investing Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
Pharmaceutical Investing Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage